# Alzheimer's Disease
## " The Role of Inflammation in Alzheimer's Disease

#Discription
Alzheimer's disease is a neurological disorder that affects the brain's ability to function properly, leading to a decline
in cognitive abilities and memory. It accounts for 60-80% of all dementia cases and is the most common form of 
the debilitating condition. The hallmark features of Alzheimer's include the accumulation of amyloid-beta plaques and tau
protein tangles in the brain,
disrupting neuronal communication and leading to neurodegeneration and cell death.
Symptoms of Alzheimer's disease typically begin with mild memory lapses, which can escalate into more pronounced memory loss.
People may also experience changes in behavior, personality, language, and spatial awareness.
The exact cause of Alzheimer's disease remains elusive, but research suggests a combination of genetic predisposition, environmental
influences, and lifestyle factors contribute to its development. Age is the most significant risk factor, with most individuals
diagnosed over 65 years old. Genetic factors, such as the APOE ε4 allele, also play a role.
Currently, there is no cure for Alzheimer's disease, but several treatments aim to manage symptoms or slow down disease progression.
These include medications like donepezil, which temporarily improve cognitive function by increasing neurotransmitters associated
with memory and learning, and non-pharmacological interventions like cognitive therapies, physical exercise programs, and social
engagement activities.


# Refferences Daft
 1.Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathologica, 82(4), 239–259.

##Reference update:
https://doi.org/10.1007/BF0030880

Summary
 Intro:  The paper by Braak and Braak presents a systematic approach to understanding neuropathological changes associated
with Alzheimer's disease. They emphasize the importance of staging these changes to better comprehend the disease's
progression and its clinical implications.

Method: The authors use post-mortem brain samples from patients diagnosed with Alzheimer's
disease to assess Alzheimer-related changes in brain tissue, identifying neurofibrillary tangles and senile plaques.
The study examines various brain regions, revealing distinct patterns of neurofibrillary tangles and plaque distribution across
different stages of the disease. They outline six stages of pathology, highlighting how these changes correlate with clinical
symptoms and cognitive decline. 

Result: The findings indicate that certain brain regions are affected earlier than others, providing
insights into the progression of Alzheimer's.

Discussion: The authors argue that their staging system offers a valuable framework for
understanding disease progression and can aid in diagnosis and treatment strategies.

#Edited Summary:
 The paper by Braak and Braak presents a systematic approach to understanding neuropathological changes associated
with Alzheimer's disease. They emphasize the importance of staging these changes to better comprehend the disease's
progression and its clinical implications.
 The authors use post-mortem brain samples from patients diagnosed with Alzheimer's
disease to assess Alzheimer-related changes in brain tissue, identifying neurofibrillary tangles and senile plaques.
The study examines various brain regions, revealing distinct patterns of neurofibrillary tangles and plaque distribution across
different stages of the disease. They outline six stages of pathology, highlighting how these changes correlate with clinical
symptoms and cognitive decline. 
The findings indicate that certain brain regions are affected earlier than others, providing
insights into the progression of Alzheimer's.
 The authors argue that their staging system offers a valuable framework for
understanding disease progression and can aid in diagnosis and treatment strategies.

Critics; Braak & Braak's 1991 article on Alzheimer's pathology has been critized for its methodology,scope,reproducibility,
and evolving scientific knowledge,necessitating ongoing research to refine our understanding


Draft Refrence
 2.Hardy, J., & Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress
and problems on the road to therapeutics. Science, 297(5580), 353–356.

Edited Refrence
https://doi.org/10.1126/science.1072994


   INTRO;   Hardy and Selkoe's (2002) paper discusses the amyloid hypothesis, which suggests that amyloid-beta peptide accumulation in the brain is
a key factor in Alzheimer's disease.
   METHOD;  They review existing literature and research findings to evaluate the hypothesis's evidence and its
implications for therapeutic development.
   RESULTS; They highlight significant progress in understanding amyloid pathology, including genetic studies
linking APP and presenilin mutations to familial Alzheimer's disease and the role of amyloid plaques in neurodegeneration.
   DISCUSSION; However, theyalso address challenges like the complexity of Alzheimer's disease and translating findings into 
effective treatments.

#Edited Summary:
  Hardy and Selkoe's (2002) paper discusses the amyloid hypothesis, which suggests that amyloid-beta peptide accumulation in the brain is
a key factor in Alzheimer's disease.
 They review existing literature and research findings to evaluate the hypothesis's evidence and its
implications for therapeutic development.
Critics; Hardy & Selkoe's article establised the amyloid hypothesis, but ongoing research challenges this model, highlighting
the need for a broader perspective on AD pathology
 They highlight significant progress in understanding amyloid pathology, including genetic studies
linking APP and presenilin mutations to familial Alzheimer's disease and the role of amyloid plaques in neurodegeneration.
 However, theyalso address challenges like the complexity of Alzheimer's disease and translating findings into 
effective treatments.

Draft Refrence
 3.Iqbal, K., & Grundke-Iqbal, I. (2010). Neurofibrillary pathology in Alzheimer’s disease: A
historical perspective on the discovery of tau protein and its role in
neurodegeneration. Journal of Alzheimer’s Disease, 19(3), 1045–1054.

Edited Refrence:
https://doi.org/10.3233/JAD-2010-1287

   INTRO;  The paper by Iqbal and Grundke-Iqbal provides a historical overview of the discovery of tau protein and its role in Alzheimer's diseas
pathology.

# Additional information for 
It highlights the evolution of research on tau, its function, and its implications in neurodegeneration. The authors discuss how tau
protein becomes hyperphosphorylated in Alzheimers leading to neurofibrillary tangles, a hallmark of the condition. This pathological process
in linked to neuronal dysfunction,and cell death,understanding tau's critical role in Alzheimer's progression. The article highlights tau's
 importance as a biomaker for diagnosis and therapeutic intervention.
   
METHOD; It reviews key studies and milestones in tau research, highlighting the correlation between tau pathology and cognitive
decline in Alzheimer's patients.

#Additional information
The authors use qualitative methodology, analyzing historical documents,scientific publications
, and clinical studies to understand tau pathology over time. They highlight key milestones in tau research, including the initial
identification of tau protein and its characterization as a microtubule-associated protein. They discuss experimental approaches used
 to investigate tau's role in neurofibrillary tangles,hallmark features of Alzheimers disease. They also highlight the correlation
between tau pathology and cognitive decline emphasizing the impoetance of immunistochemecal techniques in usualizing tau deposits in the brain tissues.

   RESULT; The authors emphasize the need for continued exploration into tau-targeted interventions. The article provides detailed
analysis of the discovery of tau protein and its role in Alzheimer's disease. 

# Addtional information
The protein initially identified for stabilizing microtubules,
 has been linked to neurodegeneration when hyperphosphorylated, leading to the formation of neurofibrillary tangles,a hallmark feature
of aAlzheimer's disease. These tangles contribute to neuronal disfunction and cell death exacerbating cognitive decline. The authors highlight
key research milestones that have elucidated the relationship between tau phosphorylation and neurodegenerative processes, emphasizing tau as a
potential therapeutic target. 
    DISCUSSION; The discovery of tau protein has significantly improved our understanding of neurofibillary pathology in Alzheimer's disease.
Initially a microtubule associated protein, tau stabilizes microtubules maintaing neuronal structure and function.


#Edited Summary
 The paper by Iqbal and Grundke-Iqbal provides a historical overview of the discovery of tau protein and its role in Alzheimer's diseas
pathology.
 It reviews key studies and milestones in tau research, highlighting the correlation between tau pathology and cognitive
decline in Alzheimer's patients.
 The authors emphasize the need for continued exploration into tau-targeted interventions. The article provides detailed
analysis of the discovery of tau protein and its role in Alzheimer's disease. 
 The discovery of tau protein has significantly improved our understanding of neurofibillary pathology in Alzheimer's disease.
Initially a microtubule associated protein, tau stabilizes microtubules maintaing neuronal structure and function.



#Additional information
However, hyperphosphorylation
of tau leads to to its aggregation into neuro fibrillary tangles, a hallmark feature of the diesase. This disrupts normal cellular process and 
contributes to neurodegeneration. Research shows that that neurofibrillary tangles corelate more closely with cognitive decline then amyloid
plaques, suggesting tau pathology may be a more critical target for therapeutic intervention. Understanding the mechanisims by which tau
contibutes to neuronal dysfunction could lead to novel treatment strategies. Further studies are exploring potential biomakers related to
the pathology to enhance early diagnosis and monitor disease progression.

Critics; Iqbal & Grundke.Iqbal(2010) provide valuable insights into tau proteins and Alzehimers disease pathology, but critiques
suggest
futher depth or updated information could enhance its contribution to ongoing discussions. a historical overview of tau protein discovery
and its role in Alzheimer's disease (AD). However, it may not adequately
address recent advancements in tau research, which has evolved significantly since 2010. The article primarily focuses on tau
pathology without discussing other critical factors in AD, such as amyloid-beta plaques or neuroinflammation. The authors also 
lack critical analysis of the methodologies used in previous studies, which could enhance understanding of how past research has
shaped current perspectives. Despite tau's significance as a biomarker for AD diagnosis and progression, the article does not
explore potential therapeutic strategies targeting tau pathology, which would have been valuable for readers interested
in translational applications of tau research.

Draft Reference:
4.Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Molecular Medicine, 8(6), 595–608.

Edited Reference:
https://doi.org/10.15252/emmm.201606210

      INTRO;  Selkoe and Hardy's 2016 paper revisits the amyloid hypothesis, suggesting that the accumulation of amyloid-beta peptides in the 
brain is a key factor in Alzheimer's disease.
      METHO;  They evaluate the validity and implications of this hypothesis,
RESULT; citing various
evidence from genetic studies, biochemical analyses, and imaging techniques. 
   DISCUSSION;  The authors acknowledge the strengths and limitation
s of the amyloid hypothesis and suggest it should be combined with other theories for a more comprehensive understanding of
Alzheimer's disease

#Edited Summary:
  Selkoe and Hardy's 2016 paper revisits the amyloid hypothesis, suggesting that the accumulation of amyloid-beta peptides in the 
brain is a key factor in Alzheimer's disease.
 They evaluate the validity and implications of this hypothesis,
 citing various
evidence from genetic studies, biochemical analyses, and imaging techniques. 
 The authors acknowledge the strengths and limitation
s of the amyloid hypothesis and suggest it should be combined with other theories for a more comprehensive understanding of
Alzheimer's disease


Critics; Selkoe and Hardy's article offers a thorough analysis of the amyloid hypothesis's history and its implications for
Alzhemer's research, but also calls for a more nuanced understanding of the disease's etiology


Draft Reference:
 5.Zetterberg, H., & Blennow, K.(2018). From cerebrospinal fluid biomarkers to blood tests 
for Alzheimer’s disease: A review on current progress and future directions for research and
clinical practice.Frontiers in Aging Neuroscience, 10(1),

Edited Reference:
Article 224 https://doi.org/10.3389/fnagi.2018.00224


    INTRO;   Zetterberg and Blennow (2018) discuss the transition from CSF biomarkers to blood tests for diagnosing Alzheimer's
disease, emphasizing early detection for improved patient outcomes.
     METOOH;  They review studies comparing blood-based biomarkers and
   RESULT; find blood tests less invasive and more convenient but lack sensitivity and specificity compared to CSF biomarkers.
    DISCUSSION;  They emphasize the need for further validation in clinical settings and suggest future research to enhance diagnostic
accuracy and accessibility for
Alzheimer's disease.

# Edited Summary:
 Zetterberg and Blennow (2018) discuss the transition from CSF biomarkers to blood tests for diagnosing Alzheimer's
disease, emphasizing early detection for improved patient outcomes.
 They review studies comparing blood-based biomarkers and
   find blood tests less invasive and more convenient but lack sensitivity and specificity compared to CSF biomarkers.
 They emphasize the need for further validation in clinical settings and suggest future research to enhance diagnostic
accuracy and accessibility for
Alzheimer's disease.

Critics; Zetherbeg and Blennow's article on the transition from CSF biomakers to blood tests for Alzheimers disease has faced criticisms
for methodological issues, overestimation of blood test potential insuffient clinical application exploration,lack of ethical discussion, and vague further direction's.

6. Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer's disease.
Biological psychiatry, 68(10), 930-941.

summary:The study by Swardfager et al. (2010) investigated the relationship between inflammatory markers, specifically C-reactive protein (CRP) and interleukin-6 (IL-6), in patients with Alzheimer's Disease (AD). The researchers conducted a cross-sectional study involving a sample of individuals diagnosed with AD and a control group of healthy participants.
Blood samples were collected to measure CRP and IL-6 levels, and statistical analyses were performed to compare the levels between AD patients and the control group.

The results showed that patients with AD exhibited significantly higher levels of both CRP and IL-6 compared to the healthy control group. This elevation in inflammatory markers was interpreted as evidence supporting the hypothesis that systemic inflammation may play a role in the pathophysiology of AD. The study also indicated a correlation between increased levels of these markers and cognitive decline, suggesting that inflammation might contribute to neurodegenerative processes.

However, the study faced criticism due to its observational design, which could not establish causation from correlational data alone. Additionally, the cross-sectional nature of the study meant it only captured a snapshot in time, and the sample size may have been insufficient to generalize findings across diverse populations or stages of Alzheimer's Disease.

To build upon these findings, future research should consider longitudinal studies that track inflammatory marker levels over time in relation to cognitive decline, expand sample sizes and include diverse populations, and incorporate neuroimaging techniques to provide insights into localized brain inflammation and its relationship with systemic markers like CRP and IL-6.

7.Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., ... & Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. 
The Lancet Neurology, 14(4), 388-405.

SUMMARY:
Heneka et al.'s 2015 study investigated the role of microglial activation in Alzheimer's Disease (AD) pathology. Microglia, resident immune cells in the brain, have been linked to neurodegenerative diseases, including AD.
The researchers used a combination of in vitro and in vivo experimental approaches, using transgenic mouse models to mimic AD pathology. They assessed microglial activation, amyloid-beta deposition, and neuroinflammation, and measured cytokine levels using ELISA.

Results showed that activated microglia were significantly associated with increased amyloid-beta plaque formation in the brains of transgenic mice. These activated microglia released pro-inflammatory cytokines, contributing to neurodegeneration. Elevated levels of TNF-α and IL-1β were observed, suggesting a direct link between microglial activation and AD pathology.

However, critics pointed out potential biases due to the reliance on animal models that may not fully replicate human disease conditions. Additionally, the study's focus on specific inflammatory mediators might overlook other critical pathways involved in AD progression. The temporal dynamics of microglial activation during different stages of disease progression also require further investigation.

To address these limitations, future research should consider using multiple animal models, longitudinal studies examining the timing and nature of microglial activation, and exploring therapeutic interventions targeting microglial activity.




8.Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019). Proprotein convertase subtilisin/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer’s disease.
Frontiers in aging neuroscience, 11, 120.

SUMMARY:Adorni et al.'s 2019 study explores the role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in brain cholesterol homeostasis and its potential implications for Alzheimer's disease (AD). The study used experimental approaches, including animal models and biochemical assays, to assess changes in brain cholesterol levels and related pathways.
The results showed that PCSK9 deficiency led to altered cholesterol levels in the brain, with an increase in total cholesterol content. Reduced PCSK9 activity was associated with enhanced expression of genes involved in cholesterol transport and metabolism, suggesting that PCSK9 plays a significant role in maintaining brain cholesterol homeostasis, which could have implications for AD pathology.

However, the study has some limitations, including its reliance on animal models, its focus on male mice, and the lack of long-term effects of altered PCSK9 levels on cognitive function. Additionally, further studies involving human subjects are needed to validate these findings.

The authors recommend future research should focus on understanding the precise mechanisms by which PCSK9 influences brain cholesterol homeostasis and its potential link to Alzheimer's disease progression. They suggest exploring therapeutic strategies targeting PCSK9 to modulate cholesterol levels in the brain and potentially mitigate AD risk or progression.

9. Calsolaro, V., & Edison, P. (2016). Neuroinflammation in Alzheimer's disease: current evidence and future directions.
Alzheimer's & dementia, 12(6), 719-732.

SUMMARY;

Calsolaro and Edison (2016) discuss the growing recognition of neuroinflammation as a significant factor in the pathogenesis of Alzheimer's disease (AD). They argue that while amyloid plaques and tau tangles are traditionally seen as the primary pathological hallmarks of AD, neuroinflammatory processes play a crucial role in disease progression. They summarize various studies that have linked inflammatory markers to cognitive decline and emphasize the need for further research to understand the mechanisms underlying neuroinflammation in AD.

The authors conducted a comprehensive review of existing literature on neuroinflammation in AD, focusing on clinical and preclinical research. They found that neuroinflammation is consistently observed in patients with AD, with elevated levels of pro-inflammatory cytokines and activated microglia in brain tissues affected by AD. Correlations between these inflammatory markers and cognitive impairment suggest that inflammation may exacerbate neuronal damage and contribute to disease progression.
However, the authors acknowledge variability in study designs and methodologies across different research efforts.

Limitations of their review include heterogeneity among studies regarding sample sizes, populations studied, and methods used to measure inflammation, which can lead to inconsistent findings and complicate comparisons. They also recommend future research directions, including longitudinal studies to better assess causality between inflammatory processes and cognitive decline. They also advocate for exploring therapeutic interventions targeting inflammation as potential strategies for modifying disease progression or improving patient outcomes.

# Alzheimer's Disease
## " The Role of Inflammation in Alzheimer's Disease

INRODUCTION:Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and
behavioral changes. The exact etiology of AD remains complex, but recent research has increasingly highlighted the significant role 
that inflammation plays in its pathogenesis. Neuroinflammation refers to the inflammatory response within the central nervous system
(CNS), including the brain and spinal cord, primarily mediated by glial cells such as microglia and astrocytes. In a healthy brain,
these cells act as guardians, clearing debris and promoting repair. However, in AD, this protective mechanism can become dysregulated.

Microglia are particularly important in AD as they are responsible for phagocytosing amyloid-beta plaques, which are hallmark features
of the disease. Chronic activation of microglia can lead to a sustained inflammatory response that exacerbates neuronal damage rather 
than protecting it. Research has shown that amyloid-beta accumulation triggers an inflammatory response in the brain, leading to the
proliferation and release of pro-inflammatory cytokines such as TNF-α and IL-1β.
These cytokines can further promote neuroinflammation and contribute to synaptic dysfunction and neuronal death.

Targeting neuroinflammatory pathways presents a promising therapeutic strategy, with anti-inflammatory drugs exploring their potential
to mitigate cognitive decline in AD patients. Emerging therapies aim at modulating microglial activity or blocking specific inflammatory
pathways without compromising their protective functions. Understanding the precise mechanisms through which inflammation contributes to
Alzheimer's pathology will be crucial for developing effective interventions.

MAINBODY

:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and memory loss. Two contrasting theories
exist regarding the role of inflammation in AD pathophysiology: the Amyloid Cascade Hypothesis and the Neuroinflammation Hypothesis. 
The Amyloid Cascade Hypothesis suggests that the accumulation of amyloid-beta (Aβ) plaques in the brain is the primary event leading 
to AD, triggering a cascade of neurotoxic events, including
inflammation. This theory has been influential but has faced criticism due to failures in clinical trials targeting Aβ without significant
cognitive benefits for patients.

The Neuroinflammation Hypothesis emphasizes that inflammation itself plays a central role in the development and progression of AD, 
independent of amyloid pathology. This theory suggests that neuroinflammatory processes initiated by factors such as tau pathology,
oxidative stress, or environmental toxins can lead to chronic activation of microglia and astrocytes, contributing directly to neuronal
injury and cognitive impairment. Evidence shows elevated levels of pro-inflammatory cytokines in the brains and cerebrospinal fluid of
Alzheimer's patients, and genetic studies have identified variants associated with increased risk for AD linked to immune response pathways.

However, this hypothesis also faces challenges regarding causality, as it remains unclear whether inflammation is a cause or consequence
of Alzheimer's pathology. Both theories highlight different aspects of how inflammation may contribute to Alzheimer's disease from
opposing perspectives. The ongoing debate highlights the complexity of Alzheimer's disease and underscores the need for further research
into these mechanisms to develop effective therapeutic strategies.

The article by Hardy and Selkoe (2002) provides an in-depth analysis of the amyloid hypothesis, which suggests that the accumulation of
amyloid-beta (Aβ) peptides in the brain is a key factor in Alzheimer's disease (AD). The authors highlight significant advancements in
molecular biology and genetics, including genetic mutations linked to increased or decreased clearance of Aβ. They also discuss the role
of Aβ plaques in AD progression. However, the authors highlight several challenges in developing effective therapies targeting Aβ, such
as the complexity of AD pathology, which includes tau protein tangles, neuroinflammation, and other factors. While some clinical trials 
targeting Aβ have shown promise, many have failed to yield significant clinical benefits, raising questions about whether Aβ is the
primary target for therapy or if other pathways need to be addressed. The article reviews various therapeutic strategies, including
immunotherapy, small molecule inhibitors, and lifestyle interventions, but emphasizes that successful treatment may require a
multifaceted approach addressing multiple aspects of AD pathology. The authors conclude that while the amyloid hypothesis has led to
significant research into Alzheimer's disease, significant hurdles remain in translating this knowledge into effective treatments.

According to David J. Selkoe's 2011 article,the study found, "The origin and metabolism of amyloid beta peptides: A case for cellular processing as a basis for
therapeutic intervention in Alzheimer's disease," discusses the role of amyloid beta (Aβ) peptides in the pathogenesis of Alzheimer's
disease (AD). Aβ peptides are generated from the amyloid precursor protein (APP) through enzymatic cleavage by β-secretase and 
γ-secretase, which can aggregate to form oligomers and fibrils, which are toxic to neurons and contribute to neurodegeneration. 
The article emphasizes the importance of cellular mechanisms that regulate Aβ production and clearance, suggesting that dysregulation
in these processes may lead to AD. Selkoe details various pathways involved in the metabolism of Aβ, including its degradation by enzymes
such as neprilysin and insulin-degrading enzyme. Impaired clearance mechanisms can lead to increased levels of Aβ in the brain, 
exacerbating its pathological effects. Selkoe argues for a shift in therapeutic focus towards enhancing cellular processing mechanisms 
rather than solely targeting Aβ aggregation. Further research into small molecules or biologics that could enhance these natural 
processes is called for.

In contast to that, Heneka et al.'s article provides a detailed analysis of neuroinflammation in Alzheimer's disease (AD), highlighting
its role in the disease's pathogenesis and progression. Neuroinflammation is characterized by the activation of microglia and astrocytes,
the primary immune cells in the central nervous system. These cells are activated in response to amyloid-beta plaques and tau tangles,
leading to a cascade of inflammatory responses. The chronic activation can lead to neuronal damage and cognitive decline. Microglia play
a crucial role in maintaining brain homeostasis, but their activation can be detrimental in AD, leading to the release of pro-inflammatory
cytokines that can promote neurodegeneration. The authors also discuss genetic factors that influence microglial function and their 
association with AD risk. Astrocytes are also highlighted as key players in neuroinflammatory processes, contributing to both 
neuroprotection and neurotoxicity depending on their state of activation. The authors suggest that modulating the inflammatory response
could offer new avenues for treatment, such as anti-inflammatory drugs or therapies aimed at restoring normal microglial function. The
article emphasizes the importance of understanding neuroinflammation's dual role in AD and calls for further research to develop 
effective treatments addressing both inflammation and
neurodegeneration.

Calsolaro and Edison's 2016 article provides a comprehensive overview of neuroinflammation in Alzheimer's disease (AD), highlighting
its role in the pathophysiology of the disease and suggesting potential therapeutic targets for intervention. Neuroinflammation is a
hallmark of AD, characterized by the activation of glial cells, including microglia and astrocytes, which respond to amyloid-beta plaques 
and tau tangles, leading to a cascade of inflammatory responses. While inflammation initially serves a protective role, chronic activation
can lead to neuronal damage and exacerbate cognitive decline.

Current evidence suggests that imaging studies show increased levels of translocator protein (TSPO), indicating microglial activation in
AD patients, and elevated levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in the brains and cerebrospinal fluid of 
AD patients.

Future directions for research include targeting neuroinflammatory pathways, using anti-inflammatory drugs, modulating microglial activity, and strategies to reduce amyloid-beta accumulation. Calsolaro and Edison emphasize the critical role of neuroinflammation in Alzheimer's disease pathology and call for more extensive research into how inflammatory processes can be modulated therapeutically to slow down or halt disease
progression.

CRITIQUES:

# REFERRENCES:
1.Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathologica, 82(4), 239–259.https://doi.org/10.1007/BF0030880

 2.Hardy, J., & Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress
and problems on the road to therapeutics. Science, 297(5580), 353–356.
https://doi.org/10.1126/science.1072994

 3.Iqbal, K., & Grundke-Iqbal, I. (2010). Neurofibrillary pathology in Alzheimer’s disease: A
historical perspective on the discovery of tau protein and its role in
neurodegeneration. Journal of Alzheimer’s Disease, 19(3), 1045–1054.https://doi.org/10.3233/JAD-2010-1287

4.Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Molecular Medicine, 8(6), 595–608.https://doi.org/10.15252/emmm.201606210

5.Zetterberg, H., & Blennow, K.(2018). From cerebrospinal fluid biomarkers to blood tests 
for Alzheimer’s disease: A review on current progress and future directions for research and
clinical practice.Frontiers in Aging Neuroscience, 10(1),Article 224 https://doi.org/10.3389/fnagi.2018.00224

6. Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer's disease.
Biological psychiatry, 68(10), 930-941.

7.Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., ... & Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. 
The Lancet Neurology, 14(4), 388-405.

8.Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019). Proprotein convertase subtilisin/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer’s disease.
Frontiers in aging neuroscience, 11, 120.

9. Calsolaro, V., & Edison, P. (2016). Neuroinflammation in Alzheimer's disease: current evidence and future directions.
Alzheimer's & dementia, 12(6), 719-732.

10.Sarlus, H., & Heneka, M. T. (2017). Microglia in Alzheimer’s disease. The Journal of clinical investigation, 127(9), 3240-3249.

11.Bettinetti‐Luque, M., Trujillo‐Estrada, L., Garcia‐Fuentes, E., Andreo‐Lopez, J., Sanchez‐Varo, R., Garrido‐Sánchez, L., ... & Baglietto‐Vargas, D. (2024).
Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease.
British Journal of Pharmacology, 181(6), 840-878.

12.McGeer, P. L., & McGeer, E. G. (2015). Targeting microglia for the treatment of Alzheimer’s disease.
Expert opinion on therapeutic targets, 19(4), 497-506.

13.DiBattista, A. M., Sierra, F., & Masliah, E. (2020). NIA workshop on senescence in brain aging and Alzheimer’s disease and its related
dementias. GeroScience, 42, 389-396.






